Octreotide combined with goserelin in the therapy of advanced pancreatic cancer-results of a pilot study and review of the literature (original) (raw)
References
Allegretti A, Lionetto R, Saccomanno S, Paganuzzi M, Onetto M, Martinoli C, Rollandi G, Marugo M, Fazzuoli L, Pugliese V et il gruoppo Ligure per lo studio del pancreas (1993) LH-RH analogue treatment of adenocarcinoma of the pancreas: a phase II study. Oncology 50:77–80 PubMed Google Scholar
Andren-Sandberg A (1989) Androgen influence on exocrine pancreatic cancer. Int J Pancreatol 4:363–369 PubMed Google Scholar
Bauer W, Briner U, Doepfner W (1982) SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31:1133–1140 PubMed Google Scholar
Büchler M, Kübel R, Klapdor R (1989) Immunotherapy of pancreatic cancer with monoclonal antibody BW494: results from a multicentric phase I–II trial. In: Beger HG, Büchler M, Reisfeld RA, Schulz G (eds) Cancer therapy. Springer, Berlin Heidelberg New York, pp 32–47 Google Scholar
Canobbio L, Boccardo F, Cannata D, Gallotti P, Epis R (1992) Treatment of advanced pancreatic cancer with the somatostatin analogue BIM 23014. Cancer 69:648–650 PubMed Google Scholar
Cascinu S, Del Ferro E, Catalano G (1995) A randomised trial of octreotide vs best supportive care only in advanced cancer patients refractory to chemotherapy. Br J Cancer 71:97–101 PubMed Google Scholar
Corbishley TP, Iqbal MJ, Johnson PJ, Williams R (1984) Progesterone receptors in malignant and foetal pancreatic tissue. IRCS Med Sci 12:575–576 Google Scholar
Corbishley TP, Iqbal MJ, Wilkinson ML, Williams R (1986) Androgen receptor in human and malignant pancreatic tissue and cell lines. Cancer 57:1992–1995 PubMed Google Scholar
Del Pozo E, Neufeld K, Schlütter F (1986) Endocrine profile of a long-acting somatostatin derivate SMS 201-995. Study in normal volunteers following subcutaneous administration. Acta Endocrinol 111:433–499 PubMed Google Scholar
Fekete M, Zalatnai A, Comaru-Schally AM, Schally AV (1989a) Membrane receptors for peptides in experimental and human pancreatic cancers. Pancreas 4:521–528 PubMed Google Scholar
Fekete M, Zalatnai A, Schally AV (1989b) Presence of membrane binding sites for (d-TRP6)-luteinizing hormone-releasing hormone in experimental pancreatic cancer. Cancer Lett 45:87–91 PubMed Google Scholar
Frieß H, Büchler M, Krüger M, Beger HG (1992) Treatment of duct carcinoma of the pancreas with the LH-RH analogue buserelin. Pancreas 7:516–521 PubMed Google Scholar
Frieß H, Büchler M, Beglinger Ch, Weber A, Kunz J, Fritsch K, Beger HG (1993a) Low dose octreotide treatment is not effective in patients with advanced pancreatic cancer. Pancreas 8:540–545 PubMed Google Scholar
Frieß H, Büchler M, Ebert M, Malfertheiner P, Dennler HJ, Beger HG (1993b) Treatment of advanced pancreatic cancer with high dose octreotide. Int J Pancreatol 14:290–291 PubMed Google Scholar
Gonzalez-Barcena D, Ibarra-Olmos MA, Garcia-Carrasco F, Gutierrez-Samperso C, Comaru-Schally AM, Schally AV (1989) Influence ofd-Trp-6-LH-RH on the survival time in patients with advanced pancreatic cancer. Biomed Pharmacother 43:313–317 PubMed Google Scholar
Greenway B, Iqubal MJ, Johnson PJ & Williams R (1981) Oestrogen receptor proteins in malignant and fetal pancreas. Br Med J 283:751–753 Google Scholar
Hanna WT and Maull KI (1990) Sandostatin-induced thrombocytopenia. South Med J 83:77 Google Scholar
Hierowski MT, Liebow C, Dusapin K, Schally AV (1985) Stimulation by somatostatin of dephosphorylation of membrane proteins in pancreatic cancer MIAPa CA2 cell lines. FEBS Lett 179:252–256 PubMed Google Scholar
Huguier M, Samama G, Testart J, Mauban S, Fingerhut A, Nassar J, Houry S, Jaeck D, De Mestier P, Favre JP, Michot F, Vidrequin A, Mantion G, Veyrieres M, Fourtanier G, Lointier P, Gignoux M (1992) Treatment of adenocarcinoma of the pancreas with somatostatin and gonadoliberin (luteinizing hormone-releasing hormone). Am J Surg 146:348–353 Google Scholar
Klijn JGM, Setyono-Han B, Bakker GH, Henkelman MS, Portengen H, Foekens JA (1987) Effects of somatostatin analog (Sandostatin) treatment in experimental and human cancer. In: Klijn JGM, Paridaens R, Foekens JA (eds) Hormonal manipulation of cancer: peptides, growth factors and new (anti) steroidal agents. (EORTC monograph series, vol 18) Raven, New York, pp 459–468 Google Scholar
Klijn JGM, Hoff AM, Planting ASTh, Verweij J, Kok T, Lamberts SWJ, Portengen H, Foekens JA (1990) Treatment of patients with metastatic pancreatic and gastrointestinal tumors with the somatostatin analogue Sandostatin: a phase II study including endocrine effects. Br J Cancer 62:627–630 PubMed Google Scholar
Lamberts SWJ, Van der Lely AJ, De Herder WW, Hofland LJ (1996) Octreotide. N Engl J Med 334:246–254 PubMed Google Scholar
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214 PubMed Google Scholar
Redding TW, Schally AV (1984) Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Proc Natl Acad Sci USA 81:248–252 PubMed Google Scholar
Reubi JC, Horisberger U, Essed CE, Jeekel J, Klijn JGH, Lamberts SWJ (1988) Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas. Gastroenterology 95:760–763 PubMed Google Scholar
Rosenberg L, Barkun AN, Denis MH, Pollak M (1995) Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Cancer 75:23–28 PubMed Google Scholar
Scambia G, Benedetti BP, Baiocchi G, Perrone L, Iacobelli S, Mancuso S (1988) Antiproliferative effects of somatostatin analog SMS 201-995 on three human breast cancer cell lines. J Cancer Res Clin Oncol 144:106–108 Google Scholar
Schally AV (1988) Oncological applications of somatostatin analogues. Cancer Res 48:6977–6985 PubMed Google Scholar
Serrano MJ, Liebow C, Reilly C, Shally AV (1988) LH-RH analogue causes direct inhibition of growth of pancreatic cancer cells in culture. Pancreas 3:617 Google Scholar
Sperti C, Fasquali C, Catalini S, Alfano D'Andrea A, Militello C, Piccoli A, Pedrazzoli S (1992) Hormonal treatment of advanced pancreatic cancer with LH-RH analogue. European J Surg Oncol 18:267–271 Google Scholar
Suri P, Lipton A, Harvey HA, Wyszynski E, Dixon R, Hamilton RW (1991) Hormonal treatment of pancreatic carcinoma with GNRH and somatostatin analogs. Proc Am Soc Clin Oncol 10:302 Google Scholar
Szende B, Srkalovic G, Timar J, Mulchahey JJ, Neill JD, Lapis K, Csikos A, Szenpeshazi K, Schally A (1991) Localization of receptors for luteinizing hormone-releasing hormone in pancreatic and mammary cancer cells. Proc Natl Acad Sci USA 88:4153–4156 PubMed Google Scholar
UICC International Union against Cancer (1987) TNM Klassifikation maligner Tumoren, vol 4. Springer, Berlin Heidelberg New York Google Scholar
Wagener DJTh, Mulder PHM de, Wils JA (1994) Multimodality treatment of locally advanced pancreatic cancer. Annal Oncol 5 [Suppl 3]: 81–86 Google Scholar
Wagener DJTh, Verdonk HER, Dirix LY, Catimel G, Siegenthaler P, Buitenhuis M, Methieu-Boué, Verweij J (1995) Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 6:129–132 PubMed Google Scholar
Wong A and Chan A (1993) Survival benefit of tamoxifen therapy in adenocarcinoma of pancreas. Cancer 71:2200–2203 PubMed Google Scholar
World Health Organization (WHO) (1990) International classification of disease for oncology, 2nd edn WHO, Geneva Google Scholar
Yamada Y, Kagimoto S, Kubota A, Yasuda K, Masuda K, Someya A, Ihara Y, Li Q, Imura H, Seino S, Seino Y (1993) Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype. Biochem Biophys Res Commun 2:844–852 Google Scholar
Zalatnai A, Schally AV (1989) Treatment of_N_-nitrosobis(2-oxopropyl)amine-induced pancreatic cancer in Syrian golden hamsters withd-Trp-6-LH-RH and somatostatin analogue RC-160 microcapsules. Cancer Res 49:1810–1815 PubMed Google Scholar